PTSD: Pathophysiology, Treatment, and Military Aspects is organized by American Psychiatric Association (APA) and will be held from Oct 01, 2017 - Oct 01, 2020. This CME Conference has been approved for a maximum of 1.5 AMA PRA Category 1 Credit™.
Depending on the area sampled, between 50% and 90% of the population have been exposed to a traumatic experience during their lifetime, with 6.8% going on to experience PTSD. The impact on those exposed to military combat is dramatically higher, with 17-25% experiencing PTSD. This course discusses the pathophysiology, treatment, and military aspects of PTSD including the unique characteristics of combat operational stress as well as the currently available treatment modalities for PTSD.
• Describe key concepts of the neuroscience of traumatic stress response including fear conditioning, neural circuits and HPA dysregulation, memory reconsolidation, and epigenetic modification.
• Recognize the implications of the neurobiology of the traumatic stress for assessment, diagnosis, and treatment.
• Describe currently available treatment modalities for the treatment of PTSD within three categories: pharmacotherapy, psychotherapy, and complementary and alternative medicine.
• Determine which PTSD treatment modalities are best suited for different patients and how they can be used in combination in a clinical setting.
• Describe and recognize the unique characteristics, symptoms, and treatment of Combat Operational Stress and how they relate to military PTSD in a clinical and occupational setting.
• Detect the stigma factors and barriers that impact willingness to seek care and compliance with treatment among military and veteran patients, and recognize the screening mechanisms for identification of PTSD.
Psychiatry, Clinical Psychology